Cells, mice and humans: a single group. Worms or flies: nothing yet.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
About aging: the drug’s trials about aging. The total counts its trials for every use.
No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.
5 independent labs in 4 countries
26 trials, none about aging, 13 with no results posted
Funders: National Heart, Lung, and Blood Institute and others
Human trial5
Humans1
Animals2
Cells2
Studies in people
2 studies gave amiloride to people and measured what changed.
American journal of physiology. Heart and circulatory physiology, Mar 12, 2026
What did studies of amiloride find?
16
Studies of amiloride measured 16 outcomes, among them systolic blood pressure, glucose and arterial stiffness.
Systolic blood pressure
↓downin humans1↓downin mice1
2 studies
Amiloride decreases systolic blood pressure in humans (-5.59 mmHg (95% CI -8.10 to -3.08) at 24 weeks).
“For SBP, the amiloride group showed significant reductions of 2.96 mmHg at 12 weeks (95% CI −5.49 to −0.43; P < 0.05) and 5.59 mmHg at 24 weeks (95% CI −8.10 to −3.08; P < 0.05) relative to baseline.”
Amiloride decreases glucose in humans (-6.07 mg/dL (95% CI -8.16 to -3.98) at 24 weeks).
“Glucose concentrations in the amiloride group decreased by 3.22 mg/dL at 12 weeks (95% CI −5.33 to −1.11; P < 0.05) and by 6.07 mg/dL at 24 weeks (95% CI −8.16 to −3.98; P < 0.05) relative to baseline, with no influence of sex and age.”
Amiloride decreases arterial stiffness in humans (-0.23 m/s (95% CI -0.39 to -0.07) at 24 weeks).
“cfPWV decreased in the amiloride group from baseline by 0.24 m/s (95% CI −0.41 to −0.07) at 12 weeks (P < 0.05) and by 0.23 m/s (95% CI −0.39 to −0.07) at 24 weeks (P < 0.05”
Amiloride improves endothelium-dependent vasodilation in mice.
“This was accompanied by restoration of NO bioavailability, reduced monocyte adhesion, and marked improvement of endothelium-dependent vasodilation in exposed mouse aortic rings”
Animalswild-type mouse tissue pretreated before exposure to polystyrene (2 μm, 200 μg/mL for 24 hours)isolated thoracic aortic ring20 μM
Amiloride increases nitric oxide bioavailability in human cells (pretreatment before exposure to polystyrene (2 μm, 200 μg/mL for 24 hours)).
“This was accompanied by restoration of NO bioavailability, reduced monocyte adhesion, and marked improvement of endothelium-dependent vasodilation in exposed mouse aortic rings”
Cellspretreatment before exposure to polystyrene (2 μm, 200 μg/mL for 24 hours)human aortic endothelial cell20 μM
Amiloride decreases inflammation in human cells (pretreatment before exposure to polystyrene (2 μm, 200 μg/mL for 24 hours)).
“Pharmacological inhibition of PS uptake with amiloride in HAECs significantly reduced intracellular particle accumulation and attenuated oxidative and inflammatory signaling.”
Cellspretreatment before exposure to polystyrene (2 μm, 200 μg/mL for 24 hours)human aortic endothelial cell20 μM
Amiloride decreases oxidative stress and ROS signaling in human cells (pretreatment before exposure to polystyrene (2 μm, 200 μg/mL for 24 hours)).
“Pharmacological inhibition of PS uptake with amiloride in HAECs significantly reduced intracellular particle accumulation and attenuated oxidative and inflammatory signaling.”
Cellspretreatment before exposure to polystyrene (2 μm, 200 μg/mL for 24 hours)human aortic endothelial cell20 μM
Amiloride decreases intracellular polystyrene accumulation in human cells (pretreatment before exposure to polystyrene (2 μm, 200 μg/mL for 24 hours)).
“Pharmacological inhibition of PS uptake with amiloride in HAECs significantly reduced intracellular particle accumulation and attenuated oxidative and inflammatory signaling.”
Cellspretreatment before exposure to polystyrene (2 μm, 200 μg/mL for 24 hours)human aortic endothelial cell20 μM
In Klotho-deficient mice, renal mTORC1 activation suppressed potassium channel ROMK1 to cause hyperkalemia, which rapamycin or Klotho supplementation reversed.In Klotho-deficient mice, renal mTORC1 activation suppressed potassium channel ROMK1 to cause hyperkalemia, which rapamycin or Klotho supplementation reversed.